The US Food and Drug Administration (US FDA) is preparing to authorise Pfizer Inc and German partner BioNTech SE's Covid-19 vaccine for adolescents aged between 12 and 15 years by early next week, the New York Times reported on Monday, citing federal officials familiar with the agency's plans.

An approval is highly anticipated after the drugmakers said in March that the vaccine was found to be safe, effective and produced robust antibody responses in 12 to 15-year-olds in a clinical trial...